LI Ai-wu,ZHOU Cai-cun,XU Jian-fang,et al.Vinorelbine versus vinorelbine-carboplatin in treatment of elderly patients with advanced non-small cell lung cancer[J].同济大学学报（医学版）,2012,33(4):57-62. [点击复制]
Vinorelbine versus vinorelbine-carboplatin in treatment of elderly patients with advanced non-small cell lung cancer
LI Ai-wu,ZHOU Cai-cun,XU Jian-fang,REN Sheng-xiang,CHEN Xiao-xia,ZHU Ren
()
Abstract:
Objective To evaluate the efficacy and safety of vinorelbine versus vinorelbine-carboplatin in elderly patients with advanced non-small cell lung cancer (NSCLC) . Methods The clinical characteristics, treatment strategies and survival features of 51 elderly patients (≥75years) with NSCLC admitted between January 2006 to December 2008 were retrospectively analyzed. Results The mean therapeutic cycles of vinorelbine and vinorelbine-carboplatin group were 1.9 and 2.3 respectively (P=0.295) . Among 21 and 14 efficacy -evaluable patients in each group, the partial remission (PR) rates were 9.5% and 28. 6% respectively (P=0.191) ; the median survival time were 7. 2 (95% CI: 4. 9, 9.5) months and 9. 3 (95%CI： 4. 3, 15.7) months; and the 1,2-year survival rates were 39.7% ,10% and 45.0% ,13% (Log Rank P=0.679) . Cox regression analysis shows that patients with performance status (PS)=2 and severe comorbidities had a poorer prognosis than those with PS =0-1 and mild comorbidities (P=0.061, 0.183) . No grade 4 hematological toxicity was found, the grade 3 hematological toxicities of two groups were neutropenia (6.5%, 15.0%), leukopenia(6.5% ,10.0% ) , anemia (6.5% ,5.0% ) and thrombopenia (3.2% ,5.0% ) . Only grade 1-2 non-hematological toxicities were recorded. And no differences of toxicity profiles were found between the two groups. Conclusion Compared with single agent, vinorelbine-carboplatin seems to be a feasible treatment option with a favorable toxicity profile for elderly (≥75years) patients with advanced NSCLC. PS status and comorbidities may be the most important prognostic factors.
